BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38496757)

  • 61. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.
    Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O;
    Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
    Kozakova K; Mego M; Cheng L; Chovanec M
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome.
    Sottile ML; Gómez LC; Redondo A; Ibarra J; García MB; Gonzalez L; Vargas-Roig LM; Nadin SB
    J Histochem Cytochem; 2024 Mar; 72(3):173-188. PubMed ID: 38439738
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
    Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
    Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors.
    Rossi M; Colecchia D; Ilardi G; Acunzo M; Nigita G; Sasdelli F; Celetti A; Strambi A; Staibano S; Croce CM; Chiariello M
    Oncotarget; 2016 Apr; 7(15):20981-98. PubMed ID: 26988910
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
    De Giorgi U; Rosti G; Papiani G; Marangolo M
    Haematologica; 2002 Jan; 87(1):95-104. PubMed ID: 11801470
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Overcoming Chemotherapy Resistance in Germ Cell Tumors.
    Országhová Z; Kalavska K; Mego M; Chovanec M
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625709
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathologic findings and clinical outcomes in patients who required neoadjuvant chemotherapy before orchiectomy for testicular germ cell tumors.
    Stump JA; Acosta AM; Whaley RD; Cheng L; Fang AM; Rais-Bahrami S; Gordetsky JB
    Hum Pathol; 2022 Oct; 128():48-55. PubMed ID: 35817140
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay.
    Kopjar N; Garaj-Vrhovac V; Milas I
    Teratog Carcinog Mutagen; 2002; 22(1):13-30. PubMed ID: 11754384
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor.
    Uriol E; Sierra M; Comendador MA; Fra J; Martínez-Camblor P; Lacave AJ; Sierra LM
    Mutagenesis; 2013 Jan; 28(1):39-48. PubMed ID: 22987025
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current aspects of high-dose chemotherapy in germ-cell tumors.
    Rick O; Kollmannsberger C; Beyer J; Bokemeyer C
    Crit Rev Oncol Hematol; 2003 Sep; 47(3):237-48. PubMed ID: 12962898
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Surgical treatment confers prognostic significance in pediatric malignant mediastinal germ cell tumors.
    Huang TH; Hung GY; Weng TF; Wang FM; Lee CY; Lin DT; Chen BW; Lin KH; Wu KH; Liu HC; Chen JS; Jou ST; Hou JY; Yang YL; Chen SH; Chang HH; Chiou SS; Lin PC; Chen RL; Hsiao CC; Yen HJ; Yang CP; Chang TK; Lu MY; Cheng CN; Sheen JM; Liao YM; Su MY; Yeh TC;
    Cancer; 2022 Dec; 128(23):4139-4149. PubMed ID: 36223226
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96.
    Schneider DT; Calaminus G; Reinhard H; Gutjahr P; Kremens B; Harms D; Göbel U
    J Clin Oncol; 2000 Feb; 18(4):832-9. PubMed ID: 10673525
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
    Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
    Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.
    Richardson NH; Althouse SK; Ashkar R; Cary C; Masterson T; Foster RS; Einhorn LH; Adra N
    Clin Genitourin Cancer; 2023 Aug; 21(4):467-474. PubMed ID: 37088659
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
    Kurobe M; Kawai K; Oikawa T; Ichioka D; Kandori S; Takaoka E; Kojima T; Joraku A; Suetomi T; Miyazaki J; Nishiyama H
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):127-33. PubMed ID: 25062721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.